Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility

Alzheimer's and Dementia

Volumn 13, Issue 4, 2017, Pages 468-492

  Mortamais, Marion ^a,b   Ash, Jessica A ^c   Harrison, John ^d,e   Kaye, Jeffrey ^f   Kramer, Joel ^g   Randolph, Christopher ^h   Pose, Carine ^a   Albala, Bruce ⁱ   Ropacki, Michael ^j   Ritchie, Craig W ^k   Ritchie, Karen ^a,b,k  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c WARNEFORD HOSPITAL   (United Kingdom)

^d METIS COGNITION LTD   (United Kingdom)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

ⁱ EISAI INC   (United States)

^j First Clinical Research   (United States)

^k UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

Alzheimer's disease; Cognition; Diagnosis; Neuropsychology; Preclinical markers

Indexed keywords

AMYLOID;

ALZHEIMER DISEASE; BRAIN; COGNITION; COGNITIVE DEFECT; FUNCTIONAL NEUROIMAGING; HUMAN; NEUROANATOMY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; PRODROMAL SYMPTOM; PSYCHOLOGY;

ALZHEIMER DISEASE; COGNITION; HUMANS; NEUROPSYCHOLOGICAL TESTS; PRODROMAL SYMPTOMS;

EID: 85007349421     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.06.2365     Document Type: Review

References (95)

1. [1] Ritchie K, Ritchie CW, Yaffe K, Skoogf I, Scarmeas N. Is late-onset Alzheimer's disease really a disease of midlife? Alzheimer's Dement Transl Res Clin Interv 2015:122–130.
2. [2] Sutphen, C.L., Jasielec, M.S., Shah, A.R., Macy, E.M., Xiong, C., Vlassenko, A.G., et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical alzheimer disease during middle age. JAMA Neurol 72 (2015), 1029–1042.
3. [3] Villemagne, V.L., Pike, K.E., Chételat, G., Ellis, K.A., Mulligan, R.S., Bourgeat, P., et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69 (2011), 181–192.
4. [4] Ritchie, C.W., Molinuevo, J.L., Truyen, L., Satlin, A., Van der Geyten, S., Lovestone, S., Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry 3 (2016), 179–186.
5. [5] Ritchie, K., Carrière, I., Ritchie, C.W., Berr, C., Artero, S., Ancelin, M.L., Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ, 341, 2010, c3885.
6. [6] Jack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
7. [7] Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71 (2014), 1379–1385.
8. [8] Sperling, Ra, Aisen, P.S., Beckett, La, Bennett, Da, Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7 (2011), 280–292.
9. [9] Bäckman, L., Jones, S., Berger, A.K., Laukka, E.J., Small, B.J., Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 19 (2005), 520–531.
10. [10] Hedden, T., Oh, H., Younger, A.P., Patel, T.A., Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 80 (2013), 1341–1348.
11. [11] Besson, F.L., La Joie, R., Doeuvre, L., Gaubert, M., Mezenge, F., Egret, S., et al. Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical alzheimer's disease. J Neurosci 35 (2015), 10402–10411.
12. [12] Toledo, J.B., Bjerke, M., Chen, K., Rozycki, M., Jack, C.R., Weiner, M.W., et al. Memory, executive, and multidomain subtle cognitive impairment: Clinical and biomarker findings. Neurology 85 (2015), 144–153.
13. [13] Wirth, M., Villeneuve, S., Haase, C.M., Madison, C.M., Oh, H., Landau, S.M., et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70 (2013), 1512–1519.
14. [14] Seidenberg, M., Kay, C.D., Woodard, J.L., Nielson, K.A., Smith, J.C., Kandah, C., et al. Recognition of famous names predicts cognitive decline in healthy elders. Neuropsychology 27 (2013), 333–342.
15. [15] Dore, V., Villemagne, V.L., Bourgeat, P., Fripp, J., Acosta, O., Chetelat, G., et al. Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol 70 (2013), 903–911.
16. [16] Buckner, R.L., Andrews-Hanna, J.R., Schacter, D.L., The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124 (2008), 1–38.
17. [17] Braak, H., Braak, E., Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82 (1991), 239–259.
18. [18] Buckner, R.L., Snyder, A.Z., Shannon, B.J., LaRossa, G., Sachs, R., Fotenos, A.F., et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25 (2005), 7709–7717.
19. [19] Fleisher, A.S., Sherzai, A., Taylor, C., Langbaum, J.B.S., Chen, K., Buxton, R.B., Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. Neuroimage 47 (2009), 1678–1690.
20. [20] Kennedy, K.M., Rodrigue, K.M., Devous, M.D. Sr., Hebrank, A.C., Bischof, G.N., Park, D.C., Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. Neuroimage 62 (2012), 1–8.
21. [21] Song, H., Long, H., Zuo, X., Yu, C., Liu, B., Wang, Z., et al. APOE effects on default mode network in chinese cognitive normal elderly: relationship with clinical cognitive performance. PLoS One, 10, 2015, e0133179.
22. [22] Westlye, E.T., Lundervold, A., Rootwelt, H., Lundervold, A.J., Westlye, L.T., Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE ε4 carriers: relationships with memory performance. J Neurosci 31 (2011), 7775–7783.
23. [23] Johnson, S.C., Christian, B.T., Okonkwo, O.C., Oh, J.M., Harding, S., Xu, G., et al. Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging 35 (2014), 576–584.
24. [24] Perrotin, A., Mormino, E.C., Madison, C.M., Hayenga, A.O., Jagust, W.J., Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol 69 (2012), 223–229.
25. [25] Song, Z., Insel, P.S., Buckley, S., Yohannes, S., Mezher, A., Simonson, A., et al. Brain amyloid-beta burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderly. J Neurosci 35 (2015), 3240–3247.
26. [26] Doherty, B.M., Schultz, S.A., Oh, J.M., Koscik, R.L., Dowling, N.M., Barnhart, T.E., et al. Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Alzheimers Dement (Amst) 1 (2015), 160–169.
27. [27] Amariglio, R.E., Becker, J.A., Carmasin, J., Wadsworth, L.P., Lorius, N., Sullivan, C., et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50 (2012), 2880–2886.
28. [28] Doraiswamy, P.M., Sperling, R.A., Coleman, R.E., Johnson, K.A., Reiman, E.M., Davis, M.D., et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 79 (2012), 1636–1644.
29. [29] Sperling, R.A., Johnson, K.A., Doraiswamy, P.M., Reiman, E.M., Fleisher, A.S., Sabbagh, M.N., et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 34 (2013), 822–831.
30. [30] Lim, Y.Y., Maruff, P., Pietrzak, R.H., Ames, D., Ellis, K.A., Harrington, K., et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 137 (2014), 221–231.
31. [31] Lim, Y.Y., Villemagne, V.L., Pietrzak, R.H., Ames, D., Ellis, K.A., Harrington, K., et al. APOE epsilon4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging 36 (2015), 1239–1244.
32. [32] Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Ward, A., Huijbers, W., et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82 (2014), 1760–1767.
33. [33] Pietrzak, R.H., Lim, Y.Y., Neumeister, A., Ames, D., Ellis, K.A., Harrington, K., et al. Amyloid-beta, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. JAMA Psychiatry 72 (2015), 284–291.
34. [34] Roe, C.M., Fagan, A.M., Grant, E.A., Hassenstab, J., Moulder, K.L., Maue Dreyfus, D., et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80 (2013), 1784–1791.
35. [35] Stonnington, C.M., Chen, K., Lee, W., Locke, D.E., Dueck, A.C., Liu, X., et al. Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimers Dement 10 (2014), e1–e8.
36. [36] Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12 (2013), 357–367.
37. [37] Yotter, R.A., Doshi, J., Clark, V., Sojkova, J., Zhou, Y., Wong, D.F., et al. Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. Neurobiol Aging 34 (2013), 2835–2842.
38. [38] Sperling, R., Mormino, E., Johnson, K., The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 84 (2014), 608–622.
39. [39] Ellis, K.A., Lim, Y.Y., Harrington, K., Ames, D., Bush, A.I., Darby, D., et al. Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta. J Alzheimers Dis 34 (2013), 861–871.
40. [40] Hollands, S., Lim, Y.Y., Buckley, R., Pietrzak, R.H., Snyder, P.J., Ames, D., et al. Amyloid-beta related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. J Alzheimers Dis 43 (2015), 677–686.
41. [41] Duff, K., Foster, N.L., Dennett, K., Hammers, D.B., Zollinger, L.V., Christian, P.E., et al. Amyloid deposition and cognition in older adults: the effects of premorbid intellect. Arch Clin Neuropsychol 28 (2013), 665–671.
42. [42] Donohue, M.C., Sperling, R.A., Salmon, D.P., Rentz, D.M., Raman, R., Thomas, R.G., et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71 (2014), 961–970.
43. [43] Caselli, R.J., Locke, D.E.C., Dueck, A.C., David, S., Woodruff, B.K., Hoffman-snyder, C., et al. The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimers Dement 10 (2014), 84–92.
44. [44] Bilgel, M., An, Y., Lang, A., Prince, J., Ferrucci, L., Jedynak, B., et al. Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample. Alzheimers Dement 10 (2014), 735–742.e4.
45. [45] Blacker, D., Lee, H., Muzikansky, A., Martin, E.C., Tanzi, R., McArdle, J.J., et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 64 (2007), 862–871.
46. [46] Caselli, R.J., Dueck, A.C., Locke, D.E., Hoffman-Snyder, C.R., Woodruff, B.K., Rapcsak, S.Z., et al. Longitudinal modeling of frontal cognition in APOE ɛ4 homozygotes, heterozygotes, and noncarriers. Neurology 76 (2011), 1383–1388.
47. [47] Chen, P., Ratcliff, G., Belle, S.H., Cauley, J.A., DeKosky, S.T., Ganguli, M., Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry 58 (2001), 853–858.
48. [48] Hall, C.B., Lipton, R.B., Sliwinski, M., Stewart, W.F., A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease. Stat Med 19 (2000), 1555–1566.
49. [49] Jungwirth, S., Zehetmayer, S., Bauer, P., Weissgram, S., Tragl, K.H., Fischer, P., Prediction of Alzheimer dementia with short neuropsychological instruments. J Neural Transm (Vienna) 116 (2009), 1513–1521.
50. [50] Klages, J.D., Fisk, J.D., Rockwood, K., APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 15 (2003), 1–5.
51. [51] Riley, K.P., Snowdon, D.A., Saunders, A.M., Roses, A.D., Mortimer, J.A., Nanayakkara, N., Cognitive Function and Apolipoprotein E in Very Old Adults: Findings From the Nun Study. J Gerontol B Psychol Sci Soc Sci 55 (2000), S69–S75.
52. [52] Ritchie, K., Carriere, I., Berr, C., Amieva, H., Dartigues, J.F., Ancelin, M.L., et al. The clinical picture of Alzheimer's disease in the decade before diagnosis: clinical and biomarker trajectories. J Clin Psychiatry 77 (2016), e305–e311.
53. [53] Salmon, D.P., Ferris, S.H., Thomas, R.G., Sano, M., Cummings, J.L., Sperling, R.A., et al. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology 27 (2013), 391–401.
54. [54] Wilson, R.S., Bienias, J.L., Berry-Kravis, E., Evans, D.A., Bennett, D.A., The apolipoprotein E epsilon 2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry 73 (2002), 672–677.
55. [55] Chen, P., Ratcliff, G., Belle, S.H., Cauley, Ja, DeKosky, S.T., Ganguli, M., Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology 55 (2000), 1847–1853.
56. [56] Elias, M.F., Beiser, A., Wolf, P.A., Au, R., White, R.F., D'Agostino, R.B., The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol 57 (2000), 808–813.
57. [57] Grober, E., Hall, C.B., Lipton, R.B., Zonderman, A.B., Resnick, S.M., Kawas, C., Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 14 (2008), 266–278.
58. [58] Hofer, S.M., Christensen, H., Mackinnon, A.J., Korten, A.E., Jorm, A.F., Henderson, A.S., et al. Change in cognitive functioning associated with ApoE genotype in a community sample of older adults. Psychol Aging 17 (2002), 194–208.
59. [59] Kawas, C.H., Corrada, M.M., Brookmeyer, R., Morrison, A., Resnick, S.M., Zonderman, A.B., et al. Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology 60 (2003), 1089–1093.
60. [60] Mayeux, R., Small, S.A., Tang, M.X., Tycko, B., Stern, Y., Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging 22 (2001), 683–689.
61. [61] Amieva, H., Jacqmin-Gadda, H., Orgogozo, J.M., Le Carret, N., Helmer, C., Letenneur, L., et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 128 (2005), 1093–1101.
62. [62] Johnson, D.K., Storandt, M., Morris, J.C., Galvin, J.E., Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 66 (2009), 1254–1259.
63. [63] Saxton, J., Lopez, O.L., Ratcliff, G., Dulberg, C., Fried, L.P., Carlson, M.C., et al. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 63 (2004), 2341–2347.
64. [64] Wilson, R.S., Segawa, E., Boyle, P.A., Anagnos, S.E., Hizel, L.P., Bennett, D.A., The natural history of cognitive decline in alzheimer's disease. Psychol Aging 27 (2012), 1008–1017.
65. [65] Dik, M.G., Jonker, C., Comijs, H.C., Bouter, L.M., Twisk, J.W., van Kamp, G.J., et al. Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly. Neurology 57 (2001), 2217–2222.
66. [66] Bretsky, P., Guralnik, J.M., Launer, L., Albert, M., Seeman, T.E., The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 60 (2003), 1077–1081.
67. [67] Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., Del Tredici, K., Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112 (2006), 389–404.
68. [68] Hirni, D.I., Kivisaari, S.L., Monsch, A.U., Taylor, K.I., Distinct neuroanatomical bases of episodic and semantic memory performance in Alzheimer's disease. Neuropsychologia 51 (2013), 930–937.
69. [69] Amieva, H., Le Goff, M., Millet, X., Orgogozo, J.M., Pérès, K., Barberger-Gateau, P., et al. Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms. Ann Neurol 64 (2008), 492–498.
70. [70] Kivisaari, S.L., Tyler, L.K., Monsch, A.U., Taylor, K.I., Medial perirhinal cortex disambiguates confusable objects. Brain 135 (2012), 3757–3769.
71. [71] Monsell, S.E., Mock, C., Hassenstab, J., Roe, C.M., Cairns, N.J., Morris, J.C., et al. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology 83 (2014), 434–440.
72. [72] Rajan, K.B., Wilson, R.S., Weuve, J., Barnes, L.L., Evans, D.A., Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology 85 (2015), 898–904.
73. [73] Rapp, M.A., Reischies, F.M., Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE). Am J Geriatr Psychiatry 13 (2005), 134–141.
74. [74] Kane, M.J., Engle, R.W., The role of prefrontal cortex in working-memory capacity, executive attention, and general fluid intelligence: an individual-differences perspective. Psychon Bull Rev 9 (2002), 637–671.
75. [75] Wilson, R.S., Leurgans, S.E., Boyle, P.A., Bennett, D.A., Cognitive decline in prodromal alzheimer disease and mild cognitive impairment. Arch Neurol 68 (2011), 351–356.
76. [76] Buckner, R.L., Memory and executive function in aging and ad: Multiple factors that cause decline and reserve factors that compensate. Neuron 44 (2004), 195–208.
77. [77] Jagust, W., Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron 77 (2013), 219–234.
78. [78] Salmon, D.P., Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Curr Top Behav Neurosci 10 (2012), 187–212.
79. [79] Twamley, E.W., Ropacki, S.A., Bondi, M.W., Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. J Int Neuropsychol Soc 12 (2006), 707–735.
80. [80] Langbaum, J.B., Hendrix, S.B., Ayutyanont, N., Chen, K., Fleisher, A.S., Shah, R.C., et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement 10 (2014), 666–674.
81. [81] Ayutyanont, N., Langbaum, J.B., Hendrix, S.B., Chen, K., Fleisher, A.S., Friesenhahn, M., et al. The Alzheimer's Prevention Initiative Composite Cognitive Test Score. J Clin Psychiatry 75 (2014), 652–660.
82. [82] Kozauer, N., Katz, R., Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease. N Engl J Med 368 (2013), 1169–1171.
83. [83] Karantzoulis, S., Novitski, J., Gold, M., Randolph, C., The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in detection and characterization of mild cognitive impairment due to Alzheimer's disease. Arch Clin Neuropsychol 28 (2013), 837–844.
84. [84] Jack, C.R. Jr., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71 (2012), 765–775.
85. [85] Lim, Y.Y., Maruff, P., Schindler, R., Ott, B.R., Salloway, S., Yoo, D.C., et al. Disruption of cholinergic neurotransmission exacerbates Abeta-related cognitive impairment in preclinical Alzheimer's disease. Neurobiol Aging 36 (2015), 2709–2715.
86. [86] Snyder, P.J., Lim, Y.Y., Schindler, R., Ott, B.R., Salloway, S., Daiello, L., et al. Microdosing of scopolamine as a “cognitive stress test”: rationale and test of a very low dose in an at-risk cohort of older adults. Alzheimers Dement 10 (2014), 262–267.
87. [87] Loewenstein, D.A., Curiel, R.E., Greig, M.T., Bauer, R.M., Rosado, M., Bowers, D., et al. A novel cognitive stress test for the detection of preclinical alzheimer disease: discriminative properties and relation to amyloid load. Am J Geriatr Psychiatry 24 (2016), 804–813.
88. [88] Greene, S.J., Killiany, R.J., Hippocampal subregions are differentially affected in the progression to Alzheimer's disease. Anat Rec (Hoboken) 295 (2012), 132–140.
89. [89] Chen, K.H., Chuah, L.Y., Sim, S.K., Chee, M.W., Hippocampal region-specific contributions to memory performance in normal elderly. Brain Cogn 72 (2010), 400–407.
90. [90] Nestor, P.J., Fryer, T.D., Ikeda, M., Hodges, J.R., Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease). Eur J Neurosci 18 (2003), 2663–2667.
91. [91] Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 68 (2007), 1718–1725.
92. [92] Burgess, N., Becker, S., King, J.A., O'Keefe, J., Memory for events and their spatial context: models and experiments. Philos Trans R Soc Lond B Biol Sci 356 (2001), 1493–1503.
93. [93] Serino, S., Cipresso, P., Morganti, F., Riva, G., The role of egocentric and allocentric abilities in Alzheimer's disease: a systematic review. Ageing Res Rev 16 (2014), 32–44.
94. [94] Laukka, E.J., Macdonald, S.W., Fratiglioni, L., Bäckman, L., Preclinical cognitive trajectories differ for Alzheimer's disease and vascular dementia. J Int Neuropsychol Soc 18 (2012), 191–199.
95. [95] Riley, K.P., Jicha, G.A., Davis, D., Abner, E.L., Cooper, G.E., Stiles, N., et al. Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis 25 (2011), 707–717.